Surgery Partners (SGRY)
(Delayed Data from NSDQ)
$33.69 USD
+5.05 (17.63%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $33.75 +0.06 (0.18%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$33.69 USD
+5.05 (17.63%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $33.75 +0.06 (0.18%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Zacks News
Surgery Partners (SGRY) Meets Q2 Earnings Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 0% and 3.99%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SGRY or MEDP: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SGRY vs. MEDP: Which Stock Is the Better Value Option?
SGRY vs. MEDP: Which Stock Is the Better Value Option?
by Zacks Equity Research
SGRY vs. MEDP: Which Stock Is the Better Value Option?
Wall Street Analysts Think Surgery Partners (SGRY) Could Surge 57.53%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Surgery Partners (SGRY) points to a 57.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Teladoc (TDOC) Soars 6.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Teladoc (TDOC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 42.86% and 1.38%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
DocGo Inc. (DCGO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Motion Acquisition (DCGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Surgery Partners (SGRY) Q1 Earnings Expected to Decline
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SGRY vs. DOCS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SGRY vs. DOCS: Which Stock Is the Better Value Option?
Surgery Partners (SGRY) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Surgery Partners (SGRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Surgery Partners (SGRY) Could Rally 39.04%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Surgery Partners (SGRY) points to a 39% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Company News for Feb 27, 2024
by Zacks Equity Research
Companies in The News Are: DPZ,FRPT,SGRY,ITRI
The Zacks Analyst Blog Highlights Microsoft, Amazon.com, Surgery Partners, Nvidia and Occidental Petroleum
by Zacks Equity Research
Microsoft, Amazon.com, Surgery Partners, Nvidia and Occidental Petroleum are part of the Zacks top Analyst Blog.h
Warren Buffett's Annual Letter: Key Insights for Investors
by Sanghamitra Saha
Follow Warren Buffett's latest tips and bet on top-ranked stocks like Microsoft (MSFT), Amazon.com (AMZN), Surgery Partners (SGRY) and Nvidia (NVDA).
Here's What Key Metrics Tell Us About Surgery Partners (SGRY) Q4 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Surgery Partners (SGRY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Surgery Partners (SGRY) Beats Q4 Earnings Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 18.92% and 0.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Gear Up for Surgery Partners (SGRY) Q4 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Surgery Partners (SGRY) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
InnovAge Holding Corp. (INNV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of 0% and 4.07%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Surgery Partners (SGRY) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Surgery Partners (SGRY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Hologic's (HOLX) Q1 Earnings Beat Estimates, Gross Margin Down
by Zacks Equity Research
Hologic's (HOLX) Breast Health segment registered strong growth in Q1, primarily owing to higher capital equipment revenues.
Will a Fall in Medicaid Customers Hurt Molina's (MOH) Q4 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q4 performance is likely to have been hurt by escalating medical care costs, and a decline in Medicaid and Marketplace membership, partly offset by growing Medicare premiums.
Boston Scientific (BSX) Q4 Earnings Top, Operating Margin Falls
by Zacks Equity Research
Boston Scientific (BSX) sees an increase in organic and operational revenues in its core business segments and geographies in the reported quarter.
ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed's (RMD) Q2 results reflect cost discipline to support an acceleration in profitability.
Abbott's (ABT) Q4 Earnings Match Estimates, Margins Rise
by Zacks Equity Research
Abbott (ABT) delivers better-than-expected revenues and in-line earnings for the fourth quarter of 2023.